Zoho Sheet - KG: Income Statement-2009Q2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

King Pharma ($M)		30 Jun 2009	30 Jun 2009	31 Mar 2009	31 Dec 2008	30 Sep 2008	30 Jun 2008	31 Mar 2008	31 Dec 2007	30 Sep 2007	30 Jun 2007	31 Mar 2007
		(actual)	(predicted)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)
Revenue		$445	$440	$429	$348	$388	$397	$432	$533	$545	$543	$516
Operating Expenses
	Cost of Goods Sold	($140)	($141)	($129)	($93)	($101)	($102)	($91)	($109)	($198)	($126)	($111)
	Depreciation	($53)	($56)	($53)	($30)	($30)	($32)	($60)	($61)	($37)	($40)	($36)
	Research & development	($21)	($27)	($27)	($32)	($34)	($28)	($29)	($45)	($35)	($37)	($32)
	Selling, General & Administrative	($124)	($140)	($139)	($105)	($99)	($112)	($130)	($164)	($185)	($173)	($168)
	Special operating charges	($18)		($73)	($610)	($1)	($65)	($1)	($104)	($168)	($78)	($0)
Operating income		$90	$76	$7	($522)	$123	$58	$121	$49	($78)	$88	$168
	Gains on investments				($7)					($10)
	Gains on asset sales
	Net interest and other income	($22)	($18)	($24)	$2	$5	$4	$8	$12	$8	$7	$7
Income before taxes		$67	$59	($17)	($528)	$128	$62	$129	$61	($80)	$95	$175
	Provisions for income taxes	($29)	($22)	$6	($21)	($44)	($21)	($44)	($18)	$40	($30)	($58)
Net income before adjustments		$38	$37	($11)	($548)	$85	$41	$86	$43	($41)	$65	$116
	Minority interests
	Income from discontinued ops			$0					($0)	($0)	($0)	($0)
Net income		$38	$37	($11)	($548)	$85	$41	$86	$43	($41)	$65	$116
Earnings Per Share		$0.15	$0.15	($0.04)	($2.25)	$0.34	$0.17	$0.35	$0.18	($0.17)	$0.26	$0.48

Shares Outstanding		247.2	244	244	244	246	245	245	244	243	245	244
Price per share		$9.63		$7.07	$10.62	$9.58	$10.47	$8.70	$10.24	$11.72	$20.46	$19.67
Market Value		$2,381	$0	$1,724	$2,591	$2,357	$2,565	$2,132	$2,499	$2,848	$5,013	$4,799

Revenue growth from year-earlier		12.1%	10.9%	-0.7%	-34.8%	-28.7%	-26.9%	-16.3%
Operating income growth from year-earlier		55.2%	31.8%	-94.1%	N/A	N/A	-34.5%	-27.7%
Net income growth from year-earlier		-7.3%	-9.7%	N/A	N/A	N/A	-36.8%	-26.2%
EPS growth from year earlier		-8.2%	-9.3%	N/A	N/A	N/A	-36.8%	-26.5%

CGS/Revenue		31.5%	32.0%	30.2%	26.9%	26.1%	25.7%	21.2%	20.5%	36.3%	23.1%	21.6%
Gross Margin		68.5%	68.0%	69.8%	73.1%	73.9%	74.3%	78.8%	79.5%	63.7%	76.9%	78.4%
Depreciation/Revenue		11.9%	12.7%	12.4%	8.5%	7.6%	8.1%	13.9%	11.4%	6.7%	7.4%	6.9%
R&D/Revenue		4.8%	6.1%	6.4%	9.1%	8.7%	7.0%	6.6%	8.4%	6.4%	6.9%	6.3%
SG&A/Revenue		27.8%	31.8%	32.3%	30.2%	25.6%	28.2%	30.1%	30.8%	34.0%	31.9%	32.6%
Income tax rate		43.6%	37.0%	N/A	N/A	33.9%	33.6%	33.8%	29.9%	N/A	31.9%	33.5%


Revenue (TTM)		$1,610	$1,605	$1,562	$1,565	$1,751	$1,907	$2,053	$2,137
Net Income (TTM)		($437)	($437)	($433)	N/A	$254	N/A	N/A	N/A
EPS (TTM)		($1.78)	($1.79)	($1.77)	$0.00	$1.04	$0.00	$0.00	$0.00

Revenue growth year-on-year		-15.56%	-15.82%	-23.91%	-26.76%	N/A	N/A	N/A	N/A
Net Income growth year-on-year		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Price/Revenue (TTM)		1.48	0	1.1	1.66	1.35	1.35	1.04	1.17
Price/Earnings (TTM)		-5.45	0	-3.98	N/A	9.28	N/A	N/A	N/A

Sheet1

Sheet2

Sheet3